26.18
-3.11%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Everest Medicines
Its shares trade on HKEX under the ticker 1952.HK. It has been listed since 9 October 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.99bn and a net loss of CN¥347.2m. At that date it held total assets of CN¥7.97bn and shareholders' equity of CN¥6.19bn.
Everest Medicines Ltd. operates as a biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-10-09. The firm is focusing on the research and development of innovative drug candidate. The firm built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The firm mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Oct 2020
- Employees
- 395
- Website
- everestmedicines.com ↗
Leadership
Pay as last reported
- Mr. Wei FuExecutive Chairman of the Board, since 2017
- Mr. Ian WooPresident, Chief Financial Officer, Executive Director, since 2018CN¥18.5m
- Mr. Yongqing LuoChief Executive Officer, Executive Director, since 2022CN¥30.7m
- Dr. Wei Jennifer YangChief Scientific Officer
- Dr. Jason BrownChief Business Officer
- Ms. Leah LiuJoint Company Secretary
- Ms. Yee Wa LauJoint Company Secretary, since 2022
- Mr. Ki Chul ChoNon-Executive Director
- Mr. Feng HonggangNon-Executive Director
- Ms. Hoi Yam ChuiIndependent Non-Executive DirectorCN¥352,000
- Mr. Shidong JiangNon-Executive Independent DirectorCN¥401,000
- Mr. Yifan LiNon-Executive Independent DirectorCN¥401,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Everest Medicines Ltd. focuses on innovative drug candidates in oncology and immunology.
- The company has a strong portfolio of clinical-stage drug candidates across multiple therapeutic areas.
- Everest Medicines operates effectively in Greater China and emerging Asia Pacific markets.
Weaknesses
- The company has only 395 employees, which may limit its operational capacity.
- Everest Medicines Ltd. is a relatively new company since its IPO in 2020.
- The firm's focus on clinical-stage drug candidates may lead to high R&D costs.
Opportunities
- Expanding into new therapeutic areas like cardio-renal disease and infectious disease.
- Growing demand for biopharmaceuticals in Greater China and Asia Pacific regions.
- Potential partnerships with larger pharmaceutical companies for drug development.
Threats
- Competition from established biotech firms in the Health Care sector.
- Regulatory challenges in emerging Asia Pacific markets for drug approvals.
- Economic downturns affecting investment in biopharmaceutical R&D.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.